{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.9"}]}],"title":"GIS score 0 (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.5"}]}],"title":"GIS score 0.50 (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6"}]}],"title":"GIS score 0.75 (%)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0"}]}],"title":"GIS score 1.0 (%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1423"}],"units":"Participants"}],"description":"Objective 3: To determine the extent to which the primary and secondary prophylaxis of FN in cancer patients is in congruence with the EORTC best practice guidelines and dosing recommendations, and whether this is associated with better outcomes.\n\nANC=Absolute Neutrophil Count; GIS Score 0 (EP2006 initiated on day 0 of chemotherapy or on day 10 or later); GIS Score 0.50 (EP2006 initiated on days 7-9 of chemotherapy); GIS Score 0.75 (EP2006 initiated on days 4-6 of chemotherapy); GIS Score 1.00 (EP2006 initiated per EORTC guidelines (2010) on days 1-3 after chemotherapy)\n\nANC=Absolute Neutrophil Count; CIN=Chemotherapy-Induced Neutropenia; EORTC=European Organization for Research and Treatment in Cancer; FN=Febrile Neutropenia; GCSF=Granulocyte Colony-Stimulating Factor; GIS=Granulocyte Colony-Stimulating Factor Initiation Score","groups":[{"description":"Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006"}],"paramType":"NUMBER","populationDescription":"The evaluable sample consists of all patients who received at least one dose of study medication, had no major protocol violation and have a minimum of enrollment cycle and either one follow-up cycle or study end data with valid outcome data (i.e., ANC or completed CIN/FN data)","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"GCSF Initiation Score (GIS)","type":"PRIMARY","unitOfMeasure":"Percent of participants"}